Moreover, tumor phenotyping was performed on TMA and by using ≥1% cut-off for ER/PR positivity37,38; however, ER/PR cut-off ≥10% is used for positivity in some centers, based on previous studies demonstrating that patients with tumors with ER 1–9% and HER-2 negativity have mostly similar outcomes to those with ER ≤ 1%39–41. The gene discussed is ESR1; the disease is neoplasm.